Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952157 | 0.98 | GRIA1 (0.43) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL1447226 | 0.92 | — | — | |
| SCHEMBL12090531 | 0.87 | POLB (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14739816 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14739515 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14740248 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14740061 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14739265 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14739086 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 | |
| SCHEMBL14740296 | 0.84 | GRIA1 (0.52) | POLBALDH1A1GRIA1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215989-A1 | SULFUR-CONTAINING LIPIDS | NANOVATION THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | WO | disclosed |
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-9081142-B2 | Photosensitive resin composition for a color filter and uses thereof | CHI MEI CORPORATION (TW) | 2015-07-14 | — | — | US | disclosed |
| US-20140346416-A1 | PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF | CHI MEI CORPORATION (TW) | 2014-11-27 | — | — | US | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | POLB 1321/4885ALDH1A1 4166/4885GRIA1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.